Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B
Xiuning Le(The University of Texas MD Anderson Cancer Center), Paul K. Paik(Memorial Sloan Kettering Cancer Center), Egbert F. Smit(Dutch Cancer Society), Christopher Stroh(Universität Hamburg), Ji‐Youn Han(National Cancer Centre Japan), Gordon Otto(Merck KGaA, Darmstadt (Germany)), Seung Soo Yoo(Kyungpook National University), María Sereno(Hospital Universitario Infanta Sofía), Yoon Ji Choi(Korea University Medical Center), Santiago Viteri(Instituto Oncológico Dr. Rosell), Carlos Cabrera Galvez(Hospital Universitari Sagrat Cor), Jin‐Hyoung Kang(The Catholic University of Korea Seoul St. Mary's Hospital), Luis Paz‐Ares(Hospital Universitario 12 De Octubre), Dilafruz Juraeva(Merck KGaA, Darmstadt (Germany)), Rolf Bruns(Inserm), Rémi Veillon(Centre Hospitalier Universitaire de Bordeaux), José Fuentes Pradera(Hospital Universitario de Valme), Toshiyuki Kozuki(Shikoku Cancer Center), H. Vioix(Merck KGaA, Darmstadt (Germany)), Jan P. van Meerbeeck(Antwerp University Hospital), Marina Chiara Garassino(University of Chicago), Young‐Chul Kim(Chonnam National University Hwasun Hospital), David Vicente Baz(Hospital Universitario Virgen Macarena), Choon-Hee Son(Dong-A University), Andreas Johne(Merck KGaA, Darmstadt (Germany))
Cited by 18
Related Papers
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Lung cancer: current therapies and new targeted treatments
|The Lancet|2016|3.3k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k